|
gptkbp:instanceOf
|
gptkb:drug
antidepressant
|
|
gptkbp:approvalYear
|
2023
|
|
gptkbp:approvedBy
|
gptkb:United_States
|
|
gptkbp:ATCCode
|
N06AX34
|
|
gptkbp:brand
|
gptkb:Zurzuvae
|
|
gptkbp:CASNumber
|
2250281-84-3
|
|
gptkbp:chemicalClass
|
neuroactive steroid
|
|
gptkbp:contraindication
|
severe hepatic impairment
concomitant use with strong CYP3A4 inducers
|
|
gptkbp:developedBy
|
gptkb:Biogen
gptkb:Sage_Therapeutics
|
|
gptkbp:eliminationRoute
|
urine
feces
|
|
gptkbp:form
|
oral tablet
|
|
gptkbp:halfLife
|
16-23 hours
|
|
gptkbp:hasMolecularFormula
|
C22H29N3O2S
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Zuranolone
|
|
gptkbp:KEGGID
|
D12345
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
positive allosteric modulator of GABA-A receptors
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pregnancyCategory
|
not recommended
|
|
gptkbp:prescriptionStatus
|
Rx-only
|
|
gptkbp:proteinBinding
|
99%
|
|
gptkbp:PubChem_CID
|
137460489
CHEMBL4297596
DB16362
|
|
gptkbp:relatedTo
|
gptkb:brexanolone
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
diarrhea
dizziness
fatigue
urinary tract infection
drowsiness
|
|
gptkbp:UNII
|
6K7C6D6L0G
|
|
gptkbp:usedFor
|
treatment of major depressive disorder
treatment of postpartum depression
|
|
gptkbp:bfsParent
|
gptkb:NASDAQ:SAGE
|
|
gptkbp:bfsLayer
|
6
|